ARCT - Arcturus Therapeutics Holdings Inc.

QQQ $ 468.16 $ -5.41 (-1.13 %)

DIA $ 411.36 $ -1.55 (-0.38 %)

SPY $ 558.32 $ -3.26 (-0.58 %)

TLT $ 97.88 $ -0.12 (-0.12 %)

GLD $ 231.76 $ -1.64 (-0.7 %)

Previous Close

$ 20.84

Open

Bid

$ 20.83 x 100

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 17.52 - $ 45.00

Volume

286,644

Average Volume

Market Cap

563.56M

Beta (5Y Monthly)

$ 1.48

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-05-2024	06-30-2024	10-Q
2	05-08-2024	03-31-2024	10-Q
3	03-14-2024	12-31-2023	10-K
4	11-14-2023	09-30-2023	10-Q
5	08-07-2023	06-30-2023	10-Q
6	05-09-2023	03-31-2023	10-Q
7	03-29-2023	12-31-2022	10-K
8	11-09-2022	09-30-2022	10-Q
9	08-09-2022	06-30-2022	10-Q
10	05-09-2022	03-31-2022	10-Q
11	03-01-2022	12-31-2021	10-K
12	11-09-2021	09-30-2021	10-Q
13	08-10-2021	06-30-2021	10-Q
14	05-10-2021	03-31-2021	10-Q
15	03-01-2021	12-31-2020	10-K
16	11-09-2020	09-30-2020	10-Q
17	08-10-2020	06-30-2020	10-Q
18	05-08-2020	03-31-2020	10-Q
19	03-16-2020	12-31-2019	10-K
20	11-08-2019	09-30-2019	10-Q
21	08-14-2019	06-30-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Leerink Partners Initiates Coverage On Arc...
08/12/2024 10:51:32

Leerink Partners analyst Lili Nsongo initiates coverage on Arcturus Therapeutics (NASDAQ:ARCT) with a Outperform rating and ...

HC Wainwright & Co. Maintains Buy on Arctu...
08/08/2024 20:47:29

HC Wainwright & Co. analyst Ed Arce maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and raises the price target...

Cantor Fitzgerald Reiterates Overweight on...
08/06/2024 15:23:40

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Arcturus Therapeutics (NASDAQ:ARCT) with a Overweight.

Arcturus Therapeutics Q2 2024 GAAP EPS $(0...
08/05/2024 20:05:06

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of...

HC Wainwright & Co. Reiterates Buy on Arct...
07/02/2024 10:27:07

HC Wainwright & Co. analyst Ed Arce reiterates Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and maintains $60 price ta...

Arcturus Therapeutics Provides Mid-Year Up...
07/01/2024 20:02:22

ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this yearARCT-810 to exp...

cathie-wood-led-ark-invest-dumps-43m-worth-of-nvidia-shares-amid-rebound--swoops-into-buy-stock-of-this-netflix-rival

Cathie Wood-Led Ark Invest Dumps $4.3M Wor...
06/26/2024 02:27:55

cathie-wood-led-ark-invest-sells-15m-worth-of-robinhood-shares-amid-muted-bitcoin-market--also-dumps-zoom-stock-worth-33m

Cathie Wood-Led Ark Invest Sells $1.5M Wor...
06/13/2024 03:22:25

Ark Invest, led by Cathie Wood, made significant trades on Wednesday involving Robinhood Markets Inc (NASDAQ:HOOD) and Zoom Vid...

cathie-wood-lead-ark-invest-dumps-76m-worth-of-robinhood-shares-amid-gamestop-buzz-bitcoin-choppiness

Cathie Wood-Lead Ark Invest Dumps $7.6M Wo...
06/11/2024 02:28:34

On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). ...

arcturus-inhaled-mrna-therapeutic-in-cystic-fibrosis-study-highlights-potential-amid-competitive-landscape-analyst

Arcturus' Inhaled mRNA Therapeutic In Cyst...
06/07/2024 18:44:44

Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, ...

12-health-care-stocks-moving-in-fridays-intraday-session

12 Health Care Stocks Moving In Friday's I...
06/07/2024 16:31:05

Arcturus Therapeutics Presents Phase 1 Res...
06/07/2024 14:30:59

ARCT-032 is safe and well tolerated with no serious adverse events (SAEs) in 36 study participants, including 4 adults with cys...

arcturus-therapeutics-early-cystic-fibrosis-trial-results-encouraging---analyst-cautiously-optimistic

Arcturus Therapeutics' Early Cystic Fibros...
05/28/2024 18:55:43

Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung ...

why-applied-dna-sciences-shares-are-trading-lower-by-around-68-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Why Applied DNA Sciences Shares Are Tradin...
05/28/2024 17:24:16

Nvidia, Insmed, Agios Pharmaceuticals And ...
05/28/2024 14:31:28

Market-Moving News for May 28th
05/28/2024 12:41:15

CORT: 41% | Corcept Therapeutics shares are trading higher after the company announced that its Phase 3 GRACE trial met its pri...

Arcturus Therapeutics Reports Phase 1b Dat...
05/28/2024 10:33:14

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program Business Wire Arcturus to present new Phase ...

Achilles Therapeutics And Arcturus Therape...
05/22/2024 11:07:04

CSL and Arcturus Therapeutics Announce Nat...
05/20/2024 12:42:20

Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results...

Canaccord Genuity Maintains Buy on Arcturu...
05/10/2024 18:30:57

Canaccord Genuity analyst Whitney Ijem maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target ...